InnovaRx Innova Health Strategies

D86.1

Sarcoidosis of lymph nodes

Billable FY2026 2025-10-01 → 2026-09-30
Exclusions 12 never code together
D80-D89block
Excludes1
  • autoimmune disease (systemic) NOS (M35.9)M35.9
  • functional disorders of polymorphonuclear neutrophils (D71-)D71-
  • human immunodeficiency virus [HIV] disease (B20)B20
D50-D89chapter
Excludes2
  • autoimmune disease (systemic) NOS (M35.9)M35.9
  • certain conditions originating in the perinatal period (P00-P96)P00-P96
  • complications of pregnancy, childbirth and the puerperium (O00-O9A)O00-O9A
  • congenital malformations, deformations and chromosomal abnormalities (Q00-Q99)Q00-Q99
  • endocrine, nutritional and metabolic diseases (E00-E88)E00-E88
  • human immunodeficiency virus [HIV] disease (B20)B20
  • injury, poisoning and certain other consequences of external causes (S00-T88)S00-T88
  • neoplasms (C00-D49)C00-D49
  • symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified (R00-R94)R00-R94

Excludes1 — never code together. The excluded condition and this one are mutually exclusive.

Excludes2 — not included here, but the patient may have both. Code both when documented.

Instructional notes 3
D80-D89block
Includes
  • defects in the complement system
  • immunodeficiency disorders, except human immunodeficiency virus [HIV] disease
  • sarcoidosis
Index entries leading here 3
  • Lymphogranulomatosis (malignant) — see also Lymphoma, Hodgkin
    • benign (Boeck's sarcoid) (Schaumann's) D86.1
  • Schaumann's
    • benign lymphogranulomatosis D86.1
  • Sarcoidosis D86.9
Alongside this code 5 same parent — D86
Additional references
AHA Coding Clinic® Licence required

Official coding advice for this code. Published by the American Hospital Association. Not included in this installation.

Risk adjustment

Maps to no condition category in any loaded model.

Presence is a property of the code. Untick a model to hide it everywhere.

This code

Billable
yes
Code set
FY2026
Parent
D86
Block
D80-D89
Siblings
5

Present FY2024–FY2027.